Why better change communication matters for Talking Medicines’ workplace positioning

Tern plc

Talking Medicines is using a familiar workplace challenge to sharpen the case for its employee insight offering. In its latest commentary on change communication, the company focuses on a problem that remains highly relevant for employers: as organisations move through repeated rounds of transformation, the volume of internal messaging rises, but clarity does not always keep pace.

New technologies, changing work models and shifting business priorities are creating an environment in which employees are regularly asked to adapt. Against that backdrop, Talking Medicines argues that communication has become a critical management function, not simply an administrative task.

It places the company’s PeopleVoice proposition in a category linked to execution risk inside large organisations. If change programmes are poorly understood, businesses can face slower adoption, weaker engagement and reduced confidence among staff. By aligning its offer with that pressure point, Talking Medicines is presenting its technology as part of the infrastructure needed to support organisational change more effectively.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Tern plc raises £450,000 in share placing ahead of AIM admission

Tern plc has raised £450,000 through a placing and outlined expected admission timing and updated voting rights.

Search